Neuropathix, Inc.
NPTX · OTC
3/31/2022 | 12/31/2021 | 9/30/2021 | 6/30/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 37.3% | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 284% | -400.7% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -913.6% | -499.6% | – | – |
| EPS Diluted | -0.021 | -0.009 | -0.008 | -0.009 |
| % Growth | -139.5% | -7.5% | 5.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |